La cadena de opciones muestra datos clave de las opciones de acciones de Ionis Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Ionis Pharmaceuticals..

Ionis Pharmaceuticals (NASDAQ:IONS) Bolsa, Cadena de Opciones

Ionis Pharmaceuticals

Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.

Ionis Pharmaceuticals, Inc. - Common Stock

Ionis Pharmaceuticals Inc

IONIS PHARMACEUTICALS ORD

News

Guidance

PODD

Insulet Raises FY24 Revenue Growth To Range Of 20% - 21% (Previously 16% -19%)

Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. The company reported quarterly sales of $4.300 million which beat the analyst consensus estimate of $4.078 million by 5.44 percent. This is a 29.47 percent decrease over sales of $6.097 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

SENS

Senseonics Holdings Q3 2024 GAAP EPS $(0.04) Misses $(0.03) Estimate, Sales $4.300M Beat $4.078M Estimate

Expensify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXFY#NASDAQ">EXFY</a>) reported quarterly earnings of $0.06 per share which met the analyst consensus estimate. This is a 175 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $35.409 million which beat the analyst consensus estimate of $35.013 million by 1.13 percent. This is a 2.97 percent decrease over sales of $36.494 million the same period last year.

EXFY

Expensify Q3 2024 Adj. EPS $0.06, Inline, Sales $35.409M Beat $35.013M Estimate

Business Outlook
Five9 provides guidance based on current market conditions and expectations. Five9 emphasizes that the guidance is subject to various important cautionary factors referenced in the section entitled "Forward-Looking Statements" below, including risks and uncertainties associated with ongoing impact of macroeconomic challenges.
<ul>
<li>For the full year 2024, Five9 now expects to report:
<ul>
<li>Revenue in the range of $1.030 to $1.031 billion.</li>
<li>GAAP net loss per share in the range of $(0.30) to $(0.23), assuming basic shares outstanding of approximately 74.5 million.</li>
<li>Non-GAAP net income per share in the range of $2.36 to $2.38, assuming diluted shares outstanding of approximately 75.0 million.</li>
</ul>
</li>
<li>For the fourth quarter of 2024, Five9 expects to report:
<ul>
<li>Revenue in the range of $267.0 to $268.0 million.</li>
<li>GAAP net income per share in the range of $0.03 to $0.08, assuming diluted shares outstanding of approximately 88.6 million.</li>
<li>Non-GAAP net income per share in the range of $0.69 to $0.71, assuming diluted shares outstanding of approximately 76.0 million.</li>
</ul>
</li>
</ul>
With respect to Five9's guidance as provided above, please refer to the "Reconciliation of GAAP Net Loss to Non-GAAP net income - Guidance" table for more details, including important assumptions upon which such guidance is based.

FIVN

Five9 Sees Q4 EPS $0.69-$0.71 Vs $0.68 Est.; Revenue $267M-$268M Vs $261.15M Est.; FY24 EPS $2.36-$2.38 Vs $2.27 Est.; Revenue $1.03B-$1.031B $1.02B Vs Est.

Nerdy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRDY#NYSE">NRDY</a>) lowers FY2024 sales outlook from $196.00 million-204.00 million to $186.00 million-189.00 million.

NRDY

Nerdy Lowers FY2024 Sales Guidance from $196.00M-204.00M to $186.00M-189.00M

Nerdy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRDY#NYSE">NRDY</a>) sees Q4 sales of $44.000 million-47.000 million vs $56.97 million estimate.

Nerdy Sees Q4 Sales $44.000M-47.000M vs $56.97M Est

Rigel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIGL#NASDAQ">RIGL</a>) reported quarterly earnings of $0.70 per share which beat the analyst consensus estimate of $0.03 by 2233.33 percent. The company reported quarterly sales of $55.307 million which beat the analyst consensus estimate of $41.927 million by 31.91 percent. This is a 96.58 percent increase over sales of $28.134 million the same period last year.

RIGL

Rigel Pharmaceuticals Q3 2024 GAAP EPS $0.70 Beats $0.03 Estimate, Sales $55.307M Beat $41.927M Estimate

Sweetgreen Sees FY24 Revenue $675M-$680M Vs $678.524M Est.

Alarm.com Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRM#NASDAQ">ALRM</a>) reported quarterly earnings of $0.62 per share which beat the analyst consensus estimate of $0.49 by 26.53 percent. This is a 10.71 percent increase over earnings of $0.56 per share from the same period last year. The company reported quarterly sales of $240.50 million which beat the analyst consensus estimate of $231.46 million by 3.90 percent. This is a 8.40 percent increase over sales of $221.85 million the same period last year.

ALRM

Alarm.com Holdings Q3 Adj $0.62 Beats $0.49 Estimate, Sales $240.50M Beat $231.46M Estimate

DXC Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>) reported quarterly earnings of $0.93 per share which beat the analyst consensus estimate of $0.72 by 29.17 percent. The company reported quarterly sales of $3.24 billion which beat the analyst consensus estimate of $3.20 billion by 1.27 percent. This is a 5.68 percent decrease over sales of $3.44 billion the same period last year.

DXC Technology Q2 2025 Adj EPS $0.93 Beats $0.72 Estimate, Sales $3.24B Beat $3.20B Estimate

Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) reported quarterly losses of $(1.67) per share which missed the analyst consensus estimate of $(0.96) by 73.96 percent. The company reported quarterly sales of $32.500 million which beat the analyst consensus estimate of $32.086 million by 1.29 percent. This is a 30.07 percent decrease over sales of $46.478 million the same period last year.

CUTR

Cutera Q3 2024 Adj. EPS $(1.67) Misses $(0.96) Estimate, Sales $32.500M Beat $32.086M Estimate

Electric vehicle company Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) reported third-quarter financial results <a href="https://www.benzinga.com/earnings">after market close Thursday.</a>
Here are the key highlights.
What Happened: Rivian announced third-quarter revenue of $874 million, which missed a Street consensus estimate of $1.00 billion, according to data<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1"> from Benzinga Pro.</a>
The company reported a loss of 99 cents per share, missing a Street consensus loss of 92 cents per share.
Operating expenses in the third quarter were $777 million, down from $963 million in the third quarter of the prior year.
Rivian had production of 13,157 vehicles in the third quarter and deliveries of 10,018 vehicles in the quarter. &nbsp;
"This quarter we have made progress against our key objectives and have seen meaningful progress on our Gen 2 R1 cost structure due to the new technologies incorporated into the vehicle and manufacturing process," Rivian CEO RJ Scaringe said.
The company announced a strategic supply agreement with LG Energy Solutions Thursday. The supply agreement will help power the company's next-generation midsize electric vehicle platform.
Rivian ended the third quarter with $6.74 billion in cash and cash equivalents, which includes $1 billion of an unsecured convertible note issued to Volkswagen International America, related to the joint venture with Volkswagen (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>). The note will automatically convert into shares of Rivian Class A stock on Dec. 1, 2024.
Read Also: <a href="https://www.benzinga.com/trading-ideas/previews/24/11/41817826/rivian-q3-earnings-preview-analyst-worries-about-demand-will-company-comment-on-2024-elect">Rivian Q3 Earnings Preview: Analyst Worries About Demand, Will Company Comment On 2024 Election Impact?</a>
What's Next: Rivian said it expects to reach positive gross profit in the fourth quarter with higher revenue per unit and improved fixed costs per unit.
The company said it is making progress on the R2 vehicle.
Rivian reaffirmed its 2024 production guidance of a range of 47,000 to 49,000 and a delivery outlook of 50,5000 to 52,000 vehicles for the full year.
EBITDA guidance ranged from a loss of $2.825 billion to $2.875 billion.
"We are excited about the future and our midsize SUV, R2, which we believe will be a fundamental driver of Rivian's growth. We're also looking forward to closing our proposed joint venture with Volkswagen Group, which is expected in the fourth quarter," Scaringe said.
RIVN Price Action: Rivian stock is up 3.2% to $10.38 in after-hours trading Thursday, versus a 52-week trading range of $8.26 to $24.61.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/technicals/24/11/41814412/rivian-vs-lucid-which-ev-stock-has-the-edge-ahead-of-q3-earnings">Rivian Vs. Lucid: Which EV Stock Has The Edge Ahead Of Q3 Earnings?</a></li>
</ul>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534;WATCH LIVE: Rivian Q3 2024 Earnings Call &#x7C; $RIVN" width="500" height="281" src="https://www.youtube.com/embed/EWhgjRxRRlI?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Photo: rblfmr/Shutterstock.com

Movers

Trading Ideas

RIVN

VWAGY

Rivian Q3 Earnings Highlights: Revenue, EPS Miss, CEO Confident In Q4 Gross Profit, R2 Being 'Fundamental Driver' Of Growth

Management

RingCentral Appoints Abhey Lamba As Chief Financial Officer

SOLV

Solventum Raises 2024 Adjusted EPS Outlook From $6.30 - $6.50 To $6.50 -$6.65 (Est $6.38)

Alpha Teknova (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKNO#NASDAQ">TKNO</a>) affirms FY2024 sales outlook from $35.00 million-38.00 million to $35.00 million-38.00 million.

TKNO

Alpha Teknova Affirms FY2024 Sales Guidance from $35.00M-38.00M to $35.00M-38.00M

TASK

TaskUs Sees FY24 Revenue $988M-$990M Vs $967.360M Est; Sees Q4 Revenue $267.3M-$269.3M.

Green Dot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDOT#NYSE">GDOT</a>) lowers FY2024 Adj EPS guidance from $1.45 to $1.33-1.36 vs $1.46 analyst estimate. Raises FY2024 sales outlook from $1.60 billion-1.70 billion to $1.65 billion-1.70 billion vs $1.67 billion estimate.

GDOT

Green Dot Lowers FY2024 Adj EPS Guidance from $1.45 to $1.33-1.36 vs $1.46 Est; Raises FY2024 Sales Guidance from $1.60B-1.70B to $1.65B-1.70B vs $1.67B Est

Serve Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.18) by 11.11 percent. The company reported quarterly sales of $221.56 thousand which missed the analyst consensus estimate of $282.33 thousand by 21.53 percent.

SERV

Serve Robotics Q3 2024 GAAP EPS $(0.20) Misses $(0.18) Estimate, Sales $221.56K Miss $282.33K Estimate

Arcadium Lithium (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALTM#NYSE">ALTM</a>) reported quarterly earnings of $0.01 per share which missed the analyst consensus estimate of $0.05 by 80 percent. The company reported quarterly sales of $203.10 million which missed the analyst consensus estimate of $268.59 million by 24.38 percent.

ALTM

Arcadium Lithium Q3 2024 GAAP EPS $0.01 Misses $0.05 Estimate, Sales $203.10M Miss $268.59M Estimate

Paul Giordano, vice president of digital assets at MARA, shared his perspective on the European Union&#8217;s upcoming Markets in <a href="https://www.benzinga.com/topic/mica">crypto-assets (MiCA) regulation</a>.
MiCA aims to set clear guidelines for the cryptocurrency industry across the EU. As MiCA nears its December implementation, Giordano expects it to bring challenges and benefits to the region's crypto market, especially for exchanges and users. Giordano is scheduled to discuss these developments at the upcoming <a href="https://benzinga.swoogo.com/digital-assets/6342807">Benzinga Future of Digital Assets</a> event.
<h3 class="wp-block-heading">Compliance and Standardization</h3>
According to Giordano, MiCA is "one of the most comprehensive regulatory frameworks for cryptocurrencies to date," offering guidelines for exchanges on compliance, risk management, and market practices. 
He explained that MiCA will require exchanges to adhere to stringent standards, including Know Your Customer (KYC) and Anti-Money Laundering (AML) requirements. Although these standards may raise operational costs for some exchanges, Giordano sees them as ultimately beneficial, as they are expected to increase consumer confidence.
"MiCA will require exchanges to meet robust compliance standards, stringent KYC/AML requirements, and details on risks, market practices, and asset functionality," Giordano said, pointing to the potential for these changes to support a safer and more transparent market for users.
<figure class="wp-block-image size-full"><a href="As the digital asset market continues to mature, the convergence of regulatory shifts, M&amp;A activities, and adoption trends will define the future of this dynamic field. Benzinga's Future of Digital Assets event in New York City this November will provide industry leaders and investors with a platform to explore these developments further, offering insights into the evolving regulatory environment and the latest market dynamics."><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/03185328/905735A6-57D3-4874-9AA1-75D037842DB3-1-5.gif" alt="" class="wp-image-626858" /></a></figure>
<h3 class="wp-block-heading">Expanding Market Access</h3>
One of the regulation's key features is its passport system, enabling approved exchanges to operate across all 27 EU countries without needing separate approvals. Giordano views this as a significant advantage for exchanges looking to expand in Europe. 
By streamlining access, MiCA's passporting could help exchanges broaden their customer base and simplify regulatory hurdles. "MiCA includes a passport system, allowing authorized crypto exchanges to operate in all 27 EU countries without needing separate approvals," he added.
<h3 class="wp-block-heading">Stablecoin Oversight</h3>
In addition to standardizing exchange practices, MiCA will impose stricter rules for stablecoins, which Giordano sees as crucial to maintaining market stability. Under MiCA, stablecoins will be subject to enhanced reserve, governance, and risk management requirements, providing additional oversight to ensure reliability. Giordano believes this will strengthen user trust and further protect the market.
As MiCA's implementation approaches, Giordano anticipates a more organized and accessible crypto environment in Europe. With new compliance requirements and cross-border exchange access, he expects MiCA to drive changes that enhance user security and market reach.
<hr class="wp-block-separator has-alpha-channel-opacity" />
As the digital asset market continues to mature, the convergence of regulatory shifts, M&amp;A activities, and adoption trends will define the future of this dynamic field.&nbsp;<a href="https://www.benzinga.com/digital-assets" target="_blank" rel="noreferrer noopener">Benzinga&#8217;s Future of Digital Assets</a>&nbsp;event in New York City this November will provide industry leaders and investors with a platform to explore these developments further, offering insights into the evolving regulatory environment and the latest market dynamics.
Image via Freepik

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Events

Exclusives

Interview

Could MiCA's Passport System Open Doors Across Europe For Crypto Exchanges?

Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS – CVS Health (CVS) up 12% Vertex (VERX) up 6% I...

Morning Movers: CVS Health surges and ODP sinks following Q3 results

Ionis Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation

Ionis reaches agreement on phase 3 trial design for Angelman candidate

Ionis Pharmaceuticals, Inc. (IONS) Q3 2024 Earnings Call Transcript

Ionis Pharmaceuticals (IONS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Stringe...

Buy Rating for Ionis Pharmaceuticals: Strong Financials and Promising Clinical Developments

Yaron Werber, an analyst from TD Cowen, maintained the Buy rating on Ionis Pharmaceuticals (IONS – Research Report). The associated price target re...

Ionis Pharmaceuticals: Strategic Developments and Robust Pipeline Justify Buy Rating

Ionis Pharmaceuticals Inc. ( ($IONS) ) has released its Q3 earnings. Here is a breakdown of the information Ionis Pharmaceuticals Inc. presented to...

Ionis Pharmaceuticals Reports Q3 2024 Financial Results

In a report released today, Gena Wang from Barclays maintained a Hold rating on Ionis Pharmaceuticals (IONS – Research Report), with a price target...

Ionis Pharmaceuticals (IONS) Gets a Hold from Barclays

Wells Fargo lowered the firm's price target on Ionis Pharmaceuticals (IONS) to $77 from $82 and keeps an Overweight rating on the shares. The firm ...

Ionis Pharmaceuticals price target lowered to $77 from $82 at Wells Fargo

Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on Ionis Pharmaceuticals (IONS – Research Report) today and set a price target of $45...

Stifel Nicolaus Sticks to Its Hold Rating for Ionis Pharmaceuticals (IONS)

ATHM

AUDC

CELH

ENOV

EXAS

GMED

HNDAF

IONS

IRBT

VERX

Offerings

Press Releases

Ionis announces pricing of $500.3 million public offering

Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease

New positive donidalorsen data to be presented at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

WAINZUA (eplontersen) recommended for approval in the EU by CHMP for the treatment of adults with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis

Comments

Ionis Pharmaceuticals

Ionis Pharmaceuticals (IONS) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL